Preeclampsia - maternal risk factors and fetal growth by Ødegård, Rønnaug A.
Preeclampsia - maternal risk factors
and fetal growth
Rønnaug A. Ødegård
Dr. med. thesis
Institute of Cancer Research and Molecular Biology
Faculty of Medicine
Norwegian University of Science and Technology

CONTENTS
ACKNOWLEDGEMENTS......................................................................................................................5
ABBREVIATIONS..................................................................................................................................7
LIST OF PAPERS INCLUDED IN THIS STUDY .................................................................................9
INTRODUCTION......................................................................................................11
1 PREECLAMPSIA ...............................................................................................................................11
1.1 Incidence .................................................................................................................................11
1.2 Definition of preeclampsia ......................................................................................................11
1.3 Aetiology.................................................................................................................................12
1.4 Pathogenesis............................................................................................................................16
2 FETAL GROWTH RESTRICTION IN PREECLAMPSIA ...............................................................17
2.1 Measurements of fetal growth.................................................................................................18
2.2 Placental morphological changes in fetal growth restriction ..................................................19
2.3 Growth factors ........................................................................................................................21
2.4.1 Interleukin-6.........................................................................................................................21
2.4.2 Insulin-like growth factor I, and its binding protein 3 and 1 ................................................22
2.4.3 Leptin ...................................................................................................................................23
3 PREECLAMPSIA AND RISK OF LATER DISEASE ......................................................................24
AIMS OF THE STUDY.............................................................................................27
SUBJECTS AND METHODS ..................................................................................28
1 CASES AND CONTROLS.................................................................................................................28
2 STUDY FACTORS.............................................................................................................................30
2.1 Maternal risk factors ...............................................................................................................30
2.2 Standardised birth weight and ponderal index ........................................................................31
2.3 Assays for umbilical cord plasma analyses.............................................................................32
3 STATISTICAL ANALYSES ..............................................................................................................33
MAIN RESULTS .......................................................................................................35
DISCUSSION .............................................................................................................37
1 INTERPRETATION OF RESULTS...................................................................................................37
2 CAN THE HETEROGENEOUS MANIFESTATIONS OF PREECLAMPSIA BE PERPETUATED
BY DIFFERENT AETIOLOGICAL CONDITIONS?...........................................................................40
3 CORD PLASMA LEVELS OF GROWTH FACTORS RELATED TO ADULT DISEASES ..........43
4 MATERNAL SMOKING AND FETAL GROWTH RESTRICTION ...............................................45
CONCLUSIONS ........................................................................................................47
REFERENCES...........................................................................................................49
ERRATA.....................................................................................................................67
APPENDIX   PAPER I - V68

5Acknowledgements
This work was supported financially by the Norwegian Medical Research Council, the
Norwegian University of Science and Technology, and the Norwegian Cancer Society. Grants
from the University Hospital in Trondheim have also contributed.
A number of persons have contributed to the completion of this thesis, and in particular I
want to express may gratitude to my mentors who have guided me through these exciting
years of preeclampsia studies: Rigmor Austgulen initiated the present study, and introduced
me to research in the field of reproduction. Lars Vatten provided invaluable methodological
help, Stein Tore Nilsen organised the whole study, and Kjell Å. Salvesen provided important
clinical insight in preeclampsia and intrauterine growth.
This work was carried out at the Institute of Cancer Research and Molecular Biology, and
Department of Community Medicine and General Practice. Both departments have provided
good working facilities, and I have enjoyed the friendly and including atmosphere that
characterises both institutes. It has been a pleasure to work with Anita Haugan, and the other
collegues in the reproduction group; Shahnaz Rahimipoor, Kristin Rian, Henrik Døllner and
Knut Jørgen Arntzen. I also thank Terje Espevik, Nina Liabakk, Egil Lien, Randi Vik and
Mari Sørensen for their advices and help during the laboratory work, and Kjartan Egeberg
for computer assistance. The secretarial assistance of Dagmar Moholdt and Tove Opdahl is
highly appreciated.
This study originates from the birth clinic at the Central Hospital of Rogaland, and I
acknowledge the staff at the clinic for their thorough work with blood sampling and
registration. I owe particular gratitude to Hege Vefring who organised the blood sampling
and processing, and Margrethe Bjelland who collected the clinical data.
Finally, I want to thank my family and my friends who supported and encourraged me during
the course of this work. My husband Vidar and my children Ane and Sondre have shown
admirable patience and understanding for my absence during busy periods, and my mother
has been of invaluable help to us.
Trondheim, January 2002
Rønnaug Astri Ødegård.
6
7Abbreviations
ALAT Alanin-aminotransferase
ASAT Aspartat-aminotransferase
BWR Birth weight ratio (observed through expected birth weight)
FGR Fetal growth restriction
GH Growth hormone
HELLP Hemolysis, elevated liver enzymes and low platelet counts
IL-6 Interleukin-6
IGF-I Insulin-like growth factor-I
IGFBP-1 Insulin-like growth factor binding protein-1
IGFBP-3 Insulin-like growth factor binding protein-3
PE Preeclampsia
PL Placental lactogen
SGA Small for gestational age
SIDS Sudden infant death syndrome
MTT 3-(4,5 dimethyl-thiazol-2-yl)-2,5-di-phenyltetrazolium bromide
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INTRODUCTION
1 PREECLAMPSIA
Preeclampsia is a complex and variable maternal disturbance that ranges from a
dramatic onset at early gestation to slowly developing symptoms towards term.
Hypertension and renal involvement with proteinuria are cardinal signs, which are
often accompanied by fluid retention, blood-clotting dysfunction, and reduced organ
perfusion. HELLP (haemolysis, elevated liver enzymes, and low platelet count)
syndrome is regarded as a variant of preeclampsia, and the fulminante disease,
eclampsia, includes convulsions. Preeclampsia is the main cause of maternal and fetal
morbidity and mortality in western countries (1, 2), and in Nordic countries, 17
percent of maternal deaths have been ascribed to preeclampsia (2). Antenatal care in
Norway includes on average 12 doctor/midwife consultations per pregnancy (3), and
since blood pressure monitoring and urinary testing are main aims of the
consultations, preeclampsia is a pregnancy complication that also generates
substantial societal costs.
1.1 Incidence
The reported incidence of preeclampsia varies between 3-10 % (4, 5-8), and some of
this variation may be attributable to differences between study populations. Since
nulliparity increases the risk of developing preeclampsia (6, 9), the incidence reported
from studies encompassing both nulliparous and parous women will be strongly
influenced by the parous state of the participants. However, the reported incidence of
preeclampsia in nulliparous women also varies substantially, and (8, 10) some of this
variation may depend on the use of different diagnostic criteria for preeclampsia
between studies (11).
1.2 Definition of preeclampsia
The definition of preeclampsia varies, but all international classification systems
emphasise the need for an increase in blood pressure to at least 140/90 mm Hg after
20 weeks gestation (6, 12-15). Since blood pressure will increase in most normal
pregnancies (6), some authors also argue that there should be an additional increase in
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diastolic blood pressure of at least 15 mm Hg (15), whereas others suggest that the
diastolic blood pressure increase should be at least 25 mm Hg (6). In all but one of the
currently used classification systems, proteinuria is required for the diagnosis of
preeclampsia (12), but the cut-off for proteinuria varies. Some suggest that there
should be one sample with at least 1+ on semiquantitative dipstick, whereas others
suggest at least two separate samples with at least 2+ on the dipstick (13). There is a
general agreement, however, that severity of preeclampsia increases with increasing
blood pressure and proteinuria, and the definition of severe preeclampsia is practically
identical for all international classification systems. The occurrence of preeclampsia
at an early gestation may represent a particularly severe form of the disease (16, 17),
but there is no consensus on the classification of  early-onset preeclampsia; the
definition ranges from delivery before 30 weeks to delivery before 37 weeks of
gestation (16-20).
1.3 Aetiology
Historical perspective
Symptoms of preeclampsia and eclampsia were described already by the ancient
Greeks (21), but eclampsia was differentiated from epilepsy first in 1739 by the
French obstetrician Sauvages, and later termed Eclampsia parturentium (22). In 1843,
proteinuria was observed, and led to the view that eclampsia depended on uremic
poisoning caused by deficient renal excretion. After the detection of eclamptic
hypertension at the end of the 19th century, the disease was regarded a manifestation
of essential hypertension, brought to light and peculiarly coloured by pregnancy (22).
However, it was recognised that preeclampsia occurred only in the presence of
placental tissue, including cases with retained placental tissue and hydatiform mole,
where the fetus is absent (23). Therefore, pathology of the placenta was early
suspected as a causative factor. In 1967, Robertson and Brosens described specific
structural changes of the uteroplacental unit in preeclampsia (24), and until recently,
unsuccessful placentation has been regarded a necessary factor for preeclampsia to
develop.
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Placental factors
In normal pregnancies, the uteroplacental spiral arteries undergo major remodelling
by invading cytotrophoblast, and the muscular, intimal and endothelial layers of the
spiral arteries are replaced by trophoblast (25). Thereby the arteries are transformed to
high flow, low resistance vessels capable of meeting the needs of the fetus, and these
physiological changes include the arterial segments of the inner third of the
myometrium (Fig.1). Preeclampsia is associated with a failure of trophoblast to
transform the spiral arteries; the number of transformed arteries is reduced, and the
transformation does not reach the myometrial segments of the arteries (24, 26, 27).
Unsuccessful placentation may cause reduced placental blood flow, and subsequent
underperfusion of the placenta may induce hypoxic injuries and generate toxic
metabolites. The prevailing hypothesis over the last decade has been that toxic
metabolites from a hypoxic placenta released to the maternal circulation may cause
the generalised syndrome of preeclampsia (23). However, maldeveloped placentas are
also observed in cases of fetal growth restriction without preeclampsia (28, 29).
Moreover, most infants born after preeclamptic pregnancies have an appropriate birth
weight for their gestation, which strongly indicates predominantly normal placentas.
Therefore, it has been suggested that the determining factor for the development of
preeclampsia may be the maternal response to a normal as well as a maldeveloped
feto-placental unit (30).
Fig.1. Diagram of maternal/fetal interface showing spiral artery blood flow and villous structure.
From: Llewellyn-Jones. Fundamentals of Obstetrics and Gynaecology 1982.
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Maternal factors
Cellular and molecular components of the immune system may play an important role
in the control of normal trophoblast invasion (31, 32), and aberrant maternal immune
response against the invading trophoblast has been considered a causative factor for
shallow trophoblast invasion (32). Compared to parous women, primiparous women
are at increased risk of preeclampsia (5, 9), and the lower risk among parous women
has been interpreted as a consequence of being desensitised to similar fetal antigens
during previous pregnancies (33). This hypothesis is supported by studies reporting
reduced risk of preeclampsia in pregnancies subsequent to a long period of
cohabitation with the father; i.e. long term exposure to paternal antigens (34), and
some studies even show that change of partner may increase the risk of preeclampsia
in subsequent pregnancies (35). However, a recent study suggests that the risk of
preeclampsia among parous women is positively associated with the time interval
between the births, regardless of partner-change (Skjærven, R, personal
communication). In their study, changing partner between two births increased the
interval between births, and they suggest that differences in time interval between
births may have confounded the association between change of partner and
preeclampsia in previous studies.
Essential hypertension has consistently been associated with increased risk of
preeclampsia (36, 37), and as measured at first antenatal visit, increased blood
pressure within the normal range, also increases the risk (7, 38-40). Other micro-
vascular diseases, including Systemic Lupus Erythematosus (SLE) (41), and
metabolic disorders, including obesity, dyslipidemia, insulin resistance and diabetes
(38, 40, 42-46) are all associated with preeclampsia. Finally, increased frequency of
thrombophilic disorders is also observed in preeclampsia (47). Recently, several
authors have reported increased frequency in preeclampsia of certain genotypes
involved in vascular disease and remodelling, volume regulation, and blood pressure
control. Candidate genes include the T235 allele for angiotensinogen, factor V Leiden
mutation, and homozygosity for methylenetetrahydrofolate reductase (46, 48, 49).
Although some of these associations have been difficult to reproduce (50-52), it has
been suggested that genes involved in circulatory and metabolic regulation may also
be involved in the development of preeclampsia (51).
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A familial predisposition for preeclampsia has been documented (53),
confirming that genetic factors may contribute to its development. The risk of
preeclampsia may be two -fold higher among daughters of women who have
experienced the disease compared to women with no history of preeclampsia (54).
Furthermore, in women with severe preeclampsia, the prevalence of pre-eclampsia
and eclampsia among their daughters was significantly higher than among their
daughters-in-law (55, 56). Thereby a mother to daughter genetic predisposition is
suggested, which fits with a model of mitochondrial inheritance of preeclampsia, as
suggested by Folgerø et al. (57).
On the other hand, the single-gene model of inheritance that best explains the
overall frequency of preeclampsia is the presence of homozygosity for the same
recessive gene both in the mother and the fetus (58). Accordingly, these fetuses would
be homozygous for the recessive allele, which they would pass to their male and
female offspring. Thus, both male and female offspring would share an increased risk
of having a pregnancy complicated by preeclampsia. The studies that failed to identify
a paternal contribution included only cases with severe maternal disease. In a study
among offspring of cases of preeclampsia that included all degrees of severity, both
males and females were more likely than controls to have a child that was the product
of a preeclamptic pregnancy (59). A population-based study in Norway among men
who had children with more than one woman give further support to the observation
of a paternal contribution to the risk of preeclampsia. This study showed that men
who fathered a child with a woman whose pregnancy was complicated by
preeclampsia were nearly twice as likely to experience preeclampsia with another
woman as men without such history (60). Thus, there are indications that the maternal
and paternal contribution to the inheritance of preeclampsia may differ according to
severity of preeclampsia.
Taken together, a variety of conditions may precede the syndrome of
preeclampsia, and most likely preeclampsia results from a combination of modifier
genes and environmental factors. Still there is little knowledge about whether these
different conditions are associated with specific clinical manifestations of the
syndrome. However, if specific patterns of associations exist between maternal risk
factors and clinical subtype of preeclampsia, this may help us understand the
underlying heterogeneous pathogenesis (61).
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Smoking and preeclampsia
A reduced risk of preeclampsia in smoking women has been observed in several
studies (38, 62-66). This association is striking, since there is evidence that the
chronic metabolic alterations observed in smoking resemble the acute changes
observed in preeclampsia, including reduced ratio between levels of prostacyclin and
thromboxane A2 (67-70), features of insulin resistance (71), plasma lipoprotein
changes (71), and increased lipid peroxidation (72). Furthermore, smoking and
preeclampsia share alterations of the maternal, utero-placental and fetal vasculature
(73-76), and these vascular factors, as well as the metabolic factors may be closely
related to the aetiology of preeclampsia. Therefore, it may appear paradoxical that the
incidence of preeclampsia is reduced among smokers. It has, however, been suggested
that among smokers, normal endothelial mechanisms may be down-regulated due to
chronic, smoking-induced vascular pathology (77). Among non-pregnants, smokers
may therefore have lower blood pressure than non-smokers (78), and among pregnant
smokers, the incidence of gestational hypertension may be lower (79). In addition,
tobacco smoke may reduce blood pressure directly by vasodilating components, and
by inducing hypovolemia (80). Thus, if smoking prevents preeclampsia, the effect
may be mediated by inhibition of endothelial mechanisms that increase blood
pressure, or by direct hypotensive effects of smoking.
There is substantial knowledge regarding pathophysiological mechanisms
related to smoking. Therefore, information about smoking and the association with
various subgroups of preeclampsia may be useful to gain insight into the
heterogeneous pathology underlying preeclampsia. To our knowledge, only one
previous study has related smoking to clinical subgroups of preeclampsia (8). That
study reported that the risk of both mild and severe preeclampsia was similarly
reduced among smokers compared to non-smokers. This relation needs, however, to
be studied in more detail, and the effect of smoking in relation to early or late
preeclampsia has not yet been studied.
1.4 Pathogenesis
The generalised maternal disturbances in preeclampsia lacked explanation until
Roberts et al. in 1989 suggested that activation of the maternal endothelium may be a
fundamental process of preeclampsia (81). Implicit in this theory was that injured
17
endothelium activates the coagulation cascade, increases capillary permeability, and
no longer buffers the vasoconstricting effects of circulating pressors. Thus,
hypertension, fluid retention, clotting disturbances, and acute underperfusion of the
liver and the brain may be attributable to the effects of activated endothelium. The
prevailing hypothesis has been that induction of endothelial dysfunction in the
maternal circulation may depend on the release of toxic substances from an
underperfused and hypoxic placenta (82).
There is evidence that the endothelial function is altered in preeclampsia (83,
84), and placental release of several toxic factors have been suggested, including
tumor necrosis factor A and interleukin-1 (85), deported syncytiotrophoblast
fragments in the maternal circulation (86), and oxidised lipid products released from
local areas with placental ischemia (87). These are all factors that may induce or
enhance oxidative stress, and thereby alter the maternal endothelial function (85, 86).
Normal pregnancy may constitute a balance between oxidative stress and anti-
oxidative defence, and substances from an underperfused placenta may disturb this
balance and thereby induce preeclampsia (88). However, some of the established
maternal risk factors for preeclampsia, including hypertension and dyslipidemia are
also associated with activated endothelium (87-90). Since preeclampsia may occur
also in the presence of apparently normal placentas (91), the balance between
oxidative stress and anti-oxidative defence may be disturbed by pre-existing systemic
oxidative stress in the maternal circulation (30, 88). Thus, endothelial dysfunction in
preeclampsia may be induced by both placental and maternal factors (30).
2 FETAL GROWTH RESTRICTION IN PREECLAMPSIA
Preeclampsia increases the risk of fetal growth restriction, but the strength of
association varies substantially between studies (8, 92, 93). Some of the variation may
be explained by the fact that most studies do not distinguish between clinical
manifestations of preeclampsia. However, the few studies that have assessed the
association between clinical subtypes of preeclampsia and fetal growth have also
shown inconsistent results; some studies suggest that fetal growth is most affected in
cases with early onset (16, 19, 94), and in severe preeclampsia (8), whereas other
studies demonstrate no clear differences between subtypes of preeclampsia (92).
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A number of maternal factors are associated with fetal growth restriction, but
whether preeclampsia interferes with these factors is unclear. Maternal smoking
reduces birth weight (8, 95), and may have effects on the uteroplacental blood flow in
common with preeclampsia. Therefore, a possible synergy between these two growth-
inhibiting factors has been suggested, indicating a reduction in birth weight that is
stronger than just adding their separate effects (8, 96). However, the results of some
investigators do not suggest that preeclampsia and smoking enhance each others
effect on infant birth weight (66).
Nulliparity is another maternal factor associated with low birth weight (9), but
one small study suggested that the risk of SGA may be higher if parous women
develop preeclampsia than if preeclampsia develops in nulliparous women (97).
Furthermore, pre-pregnancy hypertension may reduce (36), and maternal obesity may
increase birth weight (98), but how these factors influence fetal growth in
preeclampsia is not known. Since all these maternal factors are related to the risk of
developing preeclampsia, one should carefully adjust for their effects when assessing
the impact of preeclampsia on fetal growth.
2.1 Measurements of fetal growth
The term fetal growth restriction (FGR) indicates that the genetic growth potential
of the fetus has not been reached, and the term should therefore be restricted to fetuses
for whom there is evidence that growth has faltered (99). Several approaches have
been used to identify this process, including serial ultrasound measurements to
demonstrate deviations from population based weigth standards (100, 101). More
recently individualised birth weight standards have been calculated by combining
birth weigh estimation based on constitutional factors such as maternal height and
weight, with a standard proportionality curve for fetal growth (102). These
individualised birth weight standards may better identify adverse neonatal outcome
than population based standards (103-105), probably due to improved identification of
infants who have not reached their genetic growth potential. Finally, reduced blood
flow in the umbilical artery as measured by Doppler ultrasound is also used to identify
compromised fetuses (106).
All these methods are time consuming and not routinely performed. Therefore,
in most studies, measures of birth size have been used as indicators of impaired fetal
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growth. SGA is a commonly used proxy for FGR, and the World Health Organisation
(WHO) has defined a cut-off for SGA as birth weight below the 10th percentile of
expected birth weight adjusted for gestational age (107). It may seem arbitrary to
define the smallest 10 % of any population of fetuses as growth restricted, since some
of these infants most likely are constitutionally small (99). However, there is strong
evidence for increased fetal and neonatal morbidity and mortality among SGA
subjects, and this may indicate an accumulation of infants who have been
compromised in utero (108-110). Thus, birth size may suffice as a proxy for fetal
growth in large populations. By reducing the cut-off for SGA to birth weights less
than the 5th percentile, or even lower, e.g. more than 2 SD below expected birth
weight, the specificity for true growth restricted infants may be increased.
It has been difficult to estimate appropriate birth weight standards for preterm
infants, since these infants birth weight may be influenced by the factor that caused
their preterm birth (111, 112). Therefore, birth weight standards derived from
ultrasonographic measurements in healthy gravidae are gaining acceptance, because
these standards reflect the weight of healthy fetuses (112, 113).
2.2 Placental morphological changes in fetal growth restriction
In preeclampsia
Being born growth restricted may be the end point of a number of conditions, and the
pathogenesis underlying FGR probably differs (114). In preeclampsia, it has been
suggested that fetal growth is restricted only when abnormal development of the
placenta causes preeclampsia (30). Thus, corresponding to the high frequency of FGR
seen in early onset preeclampsia (19), abundant placental changes often characterise
cases of preeclampsia delivered remote from term (91).
Restricted fetal growth in preeclampsia is probably due to uteroplacental
insufficiency caused by unsuccessful transformation of spiral arteries (115). In
preeclampsia a reduced number of arteries undergo the physiological development
that enables the low resistance and high flow circulation that characterises normal
pregnancy (24, 29, 116). Subsequent reduced blood flow may limit feto- maternal
exchange of gases and nutrients, that takes place in the placental terminal villi (Fig.2).
Recently, it has become evident that the placental villous response to utero-placental
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insufficiency may differ (117, 118). Most cases of FGR show increased development
of terminal villi, and thereby an increased placental capillary bed. These changes have
been interpreted as an attempt to increase the surface area for substrate exchange
(119). In a few cases of FGR, however, no such placental compensation is observed,
and the terminal villi show signs of impaired trophoblast differentiation and
accelerated ageing of syncytiotrophoblast (118-121). Since these signs of severe
placental maladaptation are observed in very preterm deliveries, the notion early
fetal growth restriction has emerged, usually defined as delivery before 35 weeks of
gestation (119). These cases may also be characterised by severely reduced umbilical
artery blood flow (118). Since preeclampsia may be associated with fetal growth
restriction both in early and late pregnancy (92), these observations may indicate that
fetal growth restriction in preeclampsia may be perpetuated by different pathological
mechanisms.
In maternal smoking
Also smoking-related fetal growth restriction may be associated with uteroplacental
insufficiency. In vitro studies suggest that maternal smoking, analogous to
preeclampsia, may restrict early cytotrophoblast differentiation (73, 74), and thereby
inhibit the placentation process. Furthermore, maternal cotinine (a major metabolite of
nicotine) levels may be directly related to uteroplacental resistance (75, 122), and
reduced intervillous perfusion of the placenta is observed in smoking mothers (76).
FETAL VESSELS
SYNCYTIOTROPHOBLAST
CYTOTROPHOBLASTS
Fig.2. Cross-section through a placental terminal villous. From: Kingdom, J et al. Oxygen and
Placental Villous Development: Origins of fetal hypoxia. Placenta 1997.
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Accordingly, syncytial necroses are observed in placentas from smokers (123), and
the placental capillary volume fraction may be reduced (124). However, a recent
observation suggests that the placental capillary bed increases in response to heavy
maternal smoking, and this has been interpreted as a compensation in order to
increase the placental surface area for substrate exchange (125).
Tobacco smoke may also restrict fetal growth by direct toxic effects of heavy
metals, including cadmium, on fetal and placental cells (126, 127). Moreover, tobacco
smoke contains carbonmonoxide, which may induce hypoxia in fetal and placental
tissues by replacement of oxygen (128). Taken together, it is evident that the
pathogenetic mechanisms that precede and accompany fetal growth restriction in
preeclampsia and maternal smoking have common characteristics, but they also differ.
2.3 Growth factors
Intrauterine tissues used to be considered solely for their role in the exchange of gas
and transfer of nutrients and waste. During the last two decades, however, there is
growing evidence that fetal membranes, maternal decidua and the placenta produce
hormones, cytokines and growth factors and, when containing hormone receptors,
also act as endocrine organs (129, 130, 131). The brain, pituitary, gonadal and
adrenocortical steroid and peptide hormones produced by intrauterine tissues are
chemically and biologically very similar to their extra-uterine counterparts, and
appear to stimulate growth at the feto-maternal interface by autocrine or paracrine
actions. In addition, peptide factors may enter the maternal and/or fetal circulation and
display endocrine effects on metabolism and fetal growth (31, 132). Accordingly,
both preeclampsia and maternal smoking are associated with reduced circulating
levels of several pregnancy-associated hormones (127). In the present study we have
measured umbilical cord plasma levels of factors known to modify fetal growth
among infants exposed to preeclampsia in utero and among controls, and the study
had statistical power to analyse the effect of smoking on cord blood levels in both
groups.
2.4.1 Interleukin-6
Interleukin-6 (IL-6) is a small cytokine secreted by immunocompetent cells,
fibroblasts and endothelial cells (133). The cytokine is highly mitogenic, and main
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functions of IL-6 are related to its stimulatory effect on hepatic production of acute
phase proteins (134), and to growth and differentiation of haematopoietic stem cells
(135). Furthermore, in normal pregnancy, IL-6 is highly expressed and secreted in
syncytiotrophoblast (136, 137), whereas in pregnancies complicated by fetal growth
restriction, low levels of IL-6 in amniotic fluid (138) and umbilical cord blood (139)
have been observed. Several in vitro observations have related IL-6 to placental and
fetal growth, including a stimulatory effect of IL-6 on trophoblast growth, invasion,
and differentiation (136). In addition, IL-6 seems to be increased in tissues that
undergo active angiogenesis, which is a crucial feature of successful placentation
(140). IL-6 also appears to stimulate the trophoblast release of essential pregnancy
hormones in an autocrine or paracrine manner (141-143). In preeclampsia, the
syncytiotrophoblast layer is morphologically disturbed (123), and the placental
angiogenesis may be severely affected (118). Correspondingly, one small study
reported reduced placental expression of IL-6 in preeclampsia, in particular in cases
with severe maternal symptoms (144). These observations may indicate that IL-6 may
play a role in fetal growth restriction related to placental insufficiency. Main placental
synthesis of steroid and protein hormones, including IL-6, takes place in
syncytiotrophoblast (141, 143), and since mixed cord blood may reflect the placental
compartment, cord blood levels of IL-6 may be an indicator of trophoblast function.
2.4.2 Insulin-like growth factor I, and its binding protein 3 and 1
There is strong evidence that the insulin-like growth factors (IGF-I and IGF-II) and
insulin-like growth factors binding proteins (IGFBPs) are essential in regulation of
somatic growth (129, 145, 146). In postnatal growth, the IGFs are controlled mainly
by Growth Hormone (GH), whereas the fetus appears not to express functional GH-
receptors until late in pregnancy (147). The regulation of fetal IGF levels is not well
described, but placental lactogen (PL) appears to stimulate fetal IGF-I production by
acting via lactogenic receptors and possibly a unique PL receptor in fetal liver cells
(147). The IGFs function as part of a complex system that includes specific cell
surface receptors, IGFBP proteases and IGFBP-related proteins (148). IGFs have
potent mitogenic, differentative, antiapoptotic and metabolic functions, and their
actions are determined by the availability of free IGF to react with the IGF receptors.
The bioavailability of IGFs is regulated by IGFBPs, and in the circulation, IGFBP-3 is
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the major binding protein (149), whereas IGFBP-1 appears to regulate acute changes
of serum IGFs (150).
IGF-I is produced by many fetal and intrauterine tissues, and may act within
these tissues in an autocrine or paracrine manner (151-153). There is also a consistent
strong and positive association between umbilical cord levels of IGF-I and infant birth
weight (151), and circulating levels of IGFBP-3 correlate with IGF-I, whereas an
inverse relation is observed between circulating IGFBP-1 and birth weight (154-156).
Thereby, IGF-I and its binding proteins may also exhibit endocrine effects, and both
the placenta, decidua and fetal liver may contribute to the circulating levels of IGF-I
and IGFBPs (148, 152, 157). However, experimental studies have shown that
placental volume may be a strong determinant of fetal IGF-I levels (158), probably by
secretion of placenta lactogen into the fetal circulation, and thereby stimulation of the
fetus own IGF-I production (147).
In pregnancies complicated by severe preeclampsia, some recent studies show
increased decidual IGFBP-1 (159, 160), and correspondingly, IGFBP-1 levels may be
increased in cord blood from preeclamptic pregnancies (161). Furthermore, cord
blood IGF-I levels may be reduced in preeclampsia (162), but there is inconsistency
between studies (163, 164). This discrepancy may be attributable to differences
between study populations both regarding severity of maternal symptoms and
presence of fetal growth restriction. Thus, it remains to be determined whether IGF-
IGFBP changes in preeclampsia are attributable to fetal growth restriction
accompanying the syndrome, or whether preeclampsia in itself influences the IGF-
IGFBP system (161).
2.4.3 Leptin
Leptin, the product of the obesity -gene (165), is produced mainly by adipocytes
(166). Animal experiments have suggested that the hormone may be active in the
feedback loop from adipose tissue stores to centres in the hypothalamus expressing
the leptin receptor (Ob-Rb). Thereby leptin affects neuroendocrine mechanisms and
regulates several hypothalamic-pituitary axes (166-168). The leptin receptor is also
expressed in a number of other organs, including kidney, liver, intestines and bones
(169-172), and by acting directly, or indirectly by altering the levels of other
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hormones, leptin appears to increase energy expenditure, decrease food intake, induce
gluconeogenesis and lipolysis (166, 167).
During normal pregnancy, leptin is highly expressed in the placenta (173,
174), and maternal circulating levels of leptin are increased, reaching a peak around
30 weeks of gestation (169). Leptin has been detected in umbilical cord blood from
week 18 of gestation, and cord blood levels of leptin increase strongly from the
middle part of third trimester towards term (175). This coincides with the
development of fetal adipose tissue (176), and the results from several studies indicate
that cord blood leptin may reflect fetal adiposity at birth (169, 175, 177-181).
However, placenta perfusion studies indicate that some of the placental leptin is
secreted to the fetal circulation, and in umbilical cord blood venous levels appear to
be higher than arterial levels. Fetal leptin levels fall rapidly after birth (182, 183), and
the arteriovenous difference disappears (184). All these observations indicate that the
placenta may be an important determinant of umbilical leptin levels.
In preeclampsia, leptin secretion from placental explants is increased (185),
and maternal levels of circulating leptin may also be increased compared to
normotensive pregnancies (186, 187). Maternal leptin levels may be increased already
at 20 weeks of gestational among those who later present with symptoms of
preeclampsia (188), and hyperleptinemia is included in the metabolic syndrome that
also includes insulin resistance and obesity (189). Leptin may induce metabolic and
circulatory changes similar to those observed in preeclampsia (186), and thereby link
obesity to preeclampsia. Whether metabolic changes related to preeclampsia are
confined to the maternal circulation, or also involve the fetus is not known, but two
small studies found no difference in cord blood leptin levels between cases of
preeclampsia and controls at term (186, 190).
3 PREECLAMPSIA AND RISK OF LATER DISEASE
Epidemiological observations have shown that low birth weight may be a risk
factor for a number of diseases in adulthood, including hypertension (191), non-
insulin dependent diabetes (192) and coronary heart disease (193, 194). The basis for
these observations is proposed to be that of in utero programming (195). That is, an
event operating at a critical or sensitive period results in a long-term change in the
structure or function of the organism, a biological phenomenon that is well-known
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from animal studies. Accordingly, fetal adaptation to inadequate nutrition may induce
permanent physiological changes that may favour development of cardiovascular
disease in adulthood. However, low birth weight is also associated with an increased
risk of cardiac diseases in both parents (196), and preeclampsia is associated with
increased risk of maternal deaths related to cardiovascular disease (197, 198).
Therefore, confounding factors among parental characteristics such as low socio-
economic status, or a specific genotype that causes both conditions may spuriously
create the association between low birth weight and coronary heart disease in
offspring. Regardless of underlying aetiology, there are several indications of
unfavourable patterns of metabolism among subjects born SGA: Cortisol level was
increased among 60  70 year old men (199), insulin levels were increased at age 20
(200), high cholesterol levels were observed at age 12 (201), and high levels of
circulating leptin were observed already at one year of age (202). Most of these
studies did not differentiate between underlying causes of low birth weight, and since
preeclampsia is a main contributor to low birth weight, both by causing prematurity
and by restricting fetal growth, preeclampsia may be linked to risk of cardiovascular
disease in offspring. Accordingly, female offspring of preeclamptic pregnancies had
slightly increased blood pressure age 17 compared to offspring of normotensive
pregnancies (203).
Evidence suggests that immune, hormonal or genetic mechanisms that induce
hypertension and preeclampsia during pregnancy may reduce the risk of breast cancer
in both the mother (204, 205) female offspring (206-208), and reduced risk is also
observed in association with placental pathology (209) and low birth weight (210).
There is substantial experimental evidence that the GH-IGF axis is involved in
proliferation of both normal breast endothelial cells (211) and breast cancer cells
(212), and high circulating levels of IGF-I/II may perpetuate several cancers (213,
214), in particular pre-menopausal breast cancer (215). Birth weight may be a
determinant for adult height, and adult height is positively associated with risk of
breast cancer (216). Perinatal indicators of fetal growth may therefore be involved in
cancer pathogenesis, and the strong association with fetal growth makes the IGF-I
system a candidate factor.
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AIMS OF THE STUDY
The principal aims of this thesis were
1)  to examine the association between maternal risk factors and the risk of
preeclampsia, and to explore whether different clinical subtypes of preeclampsia were
associated with different risk factor patterns (Paper I)
2)  to evaluate the association between different clinical manifestations of
preeclampsia and fetal growth restriction. We also wanted to explore whether
maternal factors, particularly maternal smoking, could modify the effect of
preeclampsia on fetal growth (Paper II)
3)  to study the association between cord plasma levels of  factors that may modify
fetal growth (IL-6, IGF-I, IGFBP-1 and IGFBP-3), and fetal growth restriction in
subgroups of preeclampsia, and in controls (Paper III and V). For all groups, we also
assessed the effect of maternal smoking on growth factor levels in cord plasma.
4)  to compare umbilical cord plasma levels of leptin between preeclampsia and
control pregnancies, and to assess the relation between fetal adiposity at birth and
leptin levels (Paper IV).
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SUBJECTS AND METHODS
All births from January 1993 to December 1995 at the Central Hospital in Rogaland
County, Norway constitute the base cohort wherein the present case-control study is
nested. In this region of 238,806 inhabitants (per 1995), the Central Hospital is the
only delivery unit, and in all, 12,804 deliveries took place during the study period.
The primary aim of the cohort was to study sudden infant death syndrome (SIDS),
and thus, all infants succumbed by SIDS (9 cases), are excluded from the present
study. The study has been approved by the Regional Committee for Ethics in Medical
Research, and all study subjects from whom we obtained umbilical cord blood were
included after written consent.
1 Cases and controls
Identification of cases
The Norwegian Medical Birth Registry has recorded standardised information from
all deliveries since 1967 (217). To identify study subjects, we followed three
procedures. First, the Medical Birth Registry was used to identify all women
registered with preeclampsia who delivered at Rogaland Central Hospital. Further
potential cases were identified from the midwives consecutive records at the delivery
station, and thirdly, we identified all pregnancies with proteinuria or hypertension
from the computerised hospital database. In all, 1300 (10%) women were identified as
potential cases. We reviewed the hospital records for each potential case, and included
women as cases of preeclampsia if they fulfilled the diagnostic criteria selected for
our study.
Definition of preeclampsia
We used a previously described definition of preeclampsia (218). Briefly, persistent
diastolic blood pressure of at least 90 mmHg had to develop after 20 weeks of
gestation, in addition to an increase in diastolic blood pressure of at least 25 mmHg.
Women with a baseline diastolic blood pressure of 90 mmHg or higher were included
as cases if diastolic blood pressure had increased by at least 15 mmHg. Proteinuria
was defined as 0.3 mg/l (semiquantitative dipstick 1+) in at least one urine sample
after 20 weeks of gestation without a simultaneous urinary infection. Twelve women
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with no history of hypertension had missing blood pressure data prior to 20 weeks'
gestation, but they had a diastolic blood pressure of 105 mmHg or higher at a later
visit. It was decided to include these women as cases of preeclampsia, and in all, we
identified 323 cases of preeclampsia.
Clinical subgroups of preeclampsia
We first categorised preeclampsia into mild, moderate or severe disease (Paper I and
II), as suggested by Redman (219). Mild preeclampsia was defined as diastolic blood
pressure increase of at least 25 mmHg and proteinuria 1+ on semiquantitative
dipstick. Moderate preeclampsia was defined as an increase in diastolic blood
pressure of at least 25 mmHg and proteinuria 2+ on semiquantitative dipstick, and
severe preeclampsia as diastolic blood pressure of at least 110 mmHg, increase in
diastolic blood pressure of at least 25 mm Hg, and proteinuria 3+ on semiquantitative
dipstick, or at least 500 mg/24hours. HELLP syndrome or eclampsia was
interchangeable with severe preeclampsia, and eclampsia included seizures in addition
to hypertension and proteinuria. HELLP syndrome was defined as elevated serum
liver enzyme concentrations (ASAT and/or ALAT > 70) or low platelet counts
(≤ 100,000/ml) in addition to having epigastric pain and preeclampsia. Since mild and
moderate preeclampsia had similar effects on fetal growth (Paper II), we later merged
these two groups into one group (i.e. mild preeclampsia) for the subsequent analyses
of growth factor levels in cord blood (Paper III-V).
We used termination of the pregnancy as a proxy variable for gestational age
at onset of preeclampsia. No consensus exists regarding the definition of early onset
preeclampsia, and initially we used delivery ≤ 32 weeks gestation as cut-off (Paper 1
and II). This is an arbitrary cut-off reflecting the fact that modern neonatal intensive
care rarely have problems by handling infants born after 32 weeks gestation.
However, most obstetricians try to postpone threatening premature labour until 34
weeks. When we reanalysed our data using a cut-off at 34 weeks gestation, the
impact of early onset preeclampsia on fetal growth restriction was similar to using
cut-off at 32 weeks gestation. Therefore, in order to increase the number of subjects
in the early onset group, we later used ≤ 34 weeks gestation as cut-off for early onset
preeclampsia.
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Selection of controls
As controls, the Medical Birth Registry selected two separate groups of women
without preeclampsia who gave birth at Rogaland Central Hospital during the same
period as the selection of cases. The one group of controls consisted of randomly
selected women that were frequency matched to the cases by maternal age. This
procedure was chosen because rates of pregnancy complications and adverse fetal
outcomes are higher at young and older maternal ages, and we considered it important
to adjust for mother's age. The second control group consisted of mothers who gave
birth at this clinic subsequent to case women, in order to ensure identical blood
collection between cases and controls. Initially, in the analyses of risk factors for
preeclampsia, and fetal outcome (Paper I and II), the data were analysed using the
control groups separately, but the results were consistent and very similar for both
approaches. We therefore pooled the controls into one group, and have presented all
results accordingly. We used the same approach in the analyses of umbilical cord
plasma IL-6, and present results according to the pooled control group in Paper III,
and in the subsequent Papers (IV and V).
We obtained written consent from 323 cases of preeclampsia and 650 controls,
and all were included in the analysis of maternal risk factors (Paper I). All subsequent
analyses included only singleton pregnancies with available information about
gestational age and birth weight, leaving 307 cases of preeclampsia and 619 controls
for the analyses in Paper II. In a small fraction of cases and controls, cord blood was
not available, and after excluding subjects with neonatal sepsis, we obtained cord
blood from 271 cases and 611 controls for the IL-6 analyses (Paper III). Some of the
samples contained insufficient volume for all analyses, and after excluding cases with
maternal diabetes, cord blood was available for IFG-I analyses in 258 cases and 609
controls. Furthermore, IGFBP-3 was analysed in cord blood from 255 cases and 601
controls, IGFBP-1 in 256 cases and 604 controls, and finally, leptin was analysed in
256 cases and 607 controls.
2 Study factors
2.1 Maternal risk factors
Most women attend their first antenatal doctors visit before 12 weeks of gestation
(3). The antenatal maternal data used in this study were based on the clinical
31
information obtained at this visit. Information on maternal smoking was, however,
collected from the records obtained at the routine ultrasound screening visit at 18
weeks. Smoking was initially divided into three categories; non-smokers, smoking 1-4
cigarettes per day, and smoking 5 cigarettes or more per day (Paper I).  However, few
women reported to smoke more than 10 cigarettes a day, and in the subsequent
analyses participants were dichotomised as smokers or non-smokers (Paper II  V).
Maternal weight and blood pressure were each divided into four categories: maternal
weight in four steps of 10 kg per unit with < 60 kg as reference category, and diastolic
and systolic blood pressure were categorised using an increment of 10 mm Hg per
unit, starting at 60 mm Hg and 110 mm Hg, respectively. Pre-pregnancy diseases and
parity status were also recorded and dichotomised. Pre-pregnancy diabetes is a well-
known risk factor for preeclampsia, but this condition was not analysed because it was
only present in five cases and one control.
2.2 Standardised birth weight and ponderal index
As a measure of fetal growth, we used birth size expressed as the ratio between the
observed and the expected birth weight (birth weight ratio, BWR) (220). The expected
birth weight was adjusted for sex and gestational age at birth, and birth weight ratio
was used as a measure of fetal growth in Paper II-V. We used birth weight standards
derived from weight curves based on ultrasonographic measurements in a healthy
population of pregnant Swedish women (113), and gestational age at birth was
calculated exclusively from routine ultrasonographic measurements of biparietal
diameter at 18 weeks of gestation, according to Norwegian standard curves (221).
SGA was defined as a birth weight 2SD or more below the expected birth weight
(113). This corresponds to the 2.3 percentile or approximately 840 grams reduction in
birth weight for a term infant, or more than 24% lower birth weight than expected
(birth weight ratio < 0.76). The standardised birth weight (birth weight ratio) was
divided into four clinical categories (Paper III-V): < 0.76 corresponds to SGA, and
0.76  0.89 is a broad category of relatively small infants. The category 0.90  1.09
includes infants with appropriate weight for their gestation, and the category  > 1.09
includes large babies.
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We calculated ponderal index by the equation (birth weight x 100)/ (length3)
as a measure of fetal adiposity (Paper IV), and calculated quartile levels of the index
based on the distribution among controls.
2.3 Assays for umbilical cord plasma analyses
Interleukin-6. IL- 6 bioactivity was measured by the hybridoma cell line B 13.29
clone 9, which depends on IL-6 for growth (222), and we followed the procedures for
colorimetric assays described by Tada et al (223). Details about the analyses are given
in Paper 3, but briefly, diluted plasma samples were added to B 13.29 and growth was
measured after 64 hrs by using MTT. The intra-assay variation was on average < 7%,
and the inter-assay variation 25%. Since a high intra-assay variation was expected, all
subjects were analysed in the order they were included in the study, and samples from
three cases and six controls were always interspersed on each microtitre plate.
Therefore, a relatively high inter-assay variation would only influence the results in a
random fashion, and differences between groups would be underestimated.
IGF-I, IGFBP-3 and IGFBP-1. Cord plasma IGF-I and IGFBP-3 were assayed by
commercially available radioimmunoassay kits (Mediagnost, Tuebingen, Germany).
All samples were run in duplicates, and the procedures were run as suggested by the
producer, except that we used half volumes. Cord plasma IFGBP-1 was assayed by a
commercially available enzyme immunoassay (Mediagnost, Tuebingen, Germany),
and single samples were analysed. The three assays were run in 11 sequences, and for
all three, the intra-assay variation was <4%. The inter-assay coefficients of variation
for IGF-I, IGFBP-3 and IGFBP-1 were 12%, 10%, and 16% respectively.
Leptin. Cord plasma leptin was measured by a commercially available iodine 125-
labeled human leptin radioimmunoassay kit (Linco Research, St.Charles, Minnesota,
USA). All samples were run in duplicate, and all procedures were run as suggested by
the producer, except that we used half volumes. The intraassay variation was < 10 %
on average, and the interassay coefficient of variation was < 13 %.
More details about the assays are given in the respective papers.
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3 Statistical analyses
Student t test and Mann Whitney U test were used to compare group means and
medians respectively, and Chi-square statistics were used to compare proportions.
We estimated odds ratios for maternal risk factors (Paper I) and SGA (Paper II) as a
measure of relative risk between the preeclampsia group and control group, and used
unconditional multiple logistic regression analyses to adjust for potentially
confounding factors in multivariate analyses (224). Multiple linear regression
analyses was applied in the comparison of standardised birth weight between the
study groups (Paper II), to adjust for potentially confounding factors, and to test for
statistical interactions. We also tested for linear trends in umbilical cord plasma levels
of growth factors across categories of standardised birth weight and Ponderal index by
multiple regression analyses (Paper IV-V), and Kruskal Wallis H test (Paper III). All
statistical analyses were calculated using the Statistical Package for the Social
Sciences (SPSS, Inc., Chicago, Illinois, USA), version 7.5 (Paper I) and version 10.05
(Paper II-V).
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MAIN RESULTS
Paper I  Risk factors and clinical manifestations of pre-eclampsia
Nulliparity and hypertension increased the risk of preeclampsia, with no clear
preference for any clinical subtype. High pre-pregnancy weight was related to a
higher risk of mild and moderate preeclampsia, whereas previous preeclampsia
strongly increased the risk of early onset preeclampsia (OR 42.4; 95% CI 11.9 
151.6). Maternal smoking was associated with an overall reduced risk of preeclampsia
(OR 0.6; 95%CI 0.4  0.9), but no effect of smoking was observed in the groups with
early onset or repeated preeclampsia.
Paper II  Preeclampsia and fetal growth
Severe and/or early onset preeclampsia was significantly associated with fetal growth
restriction, and the risk of having an SGA infant was substantially higher in women
with recurrent preeclampsia. In mild preeclampsia, in contrast, no reduction in birth
weight was observed.
Maternal smoking was associated with 4% reduction in birth weight in controls and
7 % birth weight reduction in preeclampsia, and the effect of smoking on birth weight
appeared to be added to that of preeclampsia. Furthermore, the combined effect of
smoking and preeclampsia on birth weight did not differ between clinical subgroups
of preeclampsia.
Paper III  Umbilical cord plasma interleukin-6 and fetal growth restriction in
preeclampsia. A population study in Norway
In severe, as opposed to mild preeclampsia, cord plasma IL-6 was lower than among
controls (P < 0.001), and in severe preeclampsia there was a sharp decrease in cord
plasma IL-6 with decreasing birth weight ratio (P trend < 0.001). By further dividing
the preeclampsia group into early and late onset, the strong association between low
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IL-6 and low birth weight ratio appeared to be present mainly in cases with early
onset disease.
Maternal smoking had no effect on cord plasma levels in preeclampsia and controls.
Paper IV  Umbilical cord plasma leptin is increased in preeclampsia
Cord plasma leptin increased strongly with gestational age and ponderal index, both
in preeclampsia and in controls, and in both groups, females had higher leptin levels
in cord plasma than males. However, at each age of gestation, the preeclampsia group
had higher leptin levels than controls when we adjusted for differences in ponderal
index, and sex between the groups (P < 0.01).
Maternal smoking had no influence on cord leptin levels for both groups.
Paper V  Relationship of insulin-like growth factor-I and insulin-like growth factor
binding proteins in umbilical cord plasma to preeclampsia and infant birth weight
Between mild preeclampsia and controls, there were no differences in IGF-I,
IGFBP-1 and IGFBP-3. In severe and early onset preeclampsia, umbilical cord
plasma IGF-I was approximately 50% lower, IGFBP-1 was more than twice as
high as in controls (both p<0.01), whereas IGFBP-3 levels did not differ
between groups. At each birth weight level, IGF-I was higher and IGFBP-1 was
lower in sever and early onset preeclampsia than among controls of similar
weight. After adjustment for gestational age, however, birth weight and severe
preeclampsia were, independent of each other, associated with IGF-I, whereas
birth weight, but not severe preeclampsia, was associated with IGFBP-1.
After adjustment for birth weight, maternal smoking had no influence on cord
plasma levels of IGF-I and its binding protein 1 and 3 in preeclampsia or among
controls (data not shown in the paper).
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DISCUSSION
1 Interpretation of results
Our case-control study was nested within a cohort of nearly 13,000 deliveries, and we
identified 323 cases of preeclampsia.
In Norway nearly 100 % of the pregnant women attend the national antenatal
care program, and thereby we had an unselected population of pregnant women
eligible for our study. However, using informed written consent as a criterion for
inclusion introduced the possibility of selecting study subjects that are not
representative for the eligible population. In the preeclampsia group, more than 96 %
of subjects who met the diagnostic criteria also gave written consent, whereas among
controls, the response rate was lower, but still close to 80 %. This is regarded as a
highly acceptable response rate, and selection bias is not likely to have had any major
influence on our results.
All information regarding pre-pregnancy data and maternal risk factors was
collected prospectively on standardised forms before symptoms of preeclampsia
occurred. This prospective recording makes it unlikely that information was recorded
differently for cases of preeclampsia and controls, and any data inaccuracies or
misclassification of exposure is probably distributed randomly among all study
subjects. Random misclassification of exposure will result in an underestimation of
the true relative risks, and the observed associations are unlikely to be spurious. In our
study, maternal smoking during pregnancy represents a variable particularly prone to
misclassification. On the one hand, there is always the possibility that the woman may
quit smoking in response to information on the adverse effects during pregnancy. On
the other hand, an underreporting of maternal smoking during pregnancy has been
indicated by studies that compare biochemical tracers of nicotine with maternal self-
reporting on smoking (225), although not confirmed by others (226). To meet the first
concern, we based our classification of smoking status on information collected at 18
weeks of gestation, since it has been suggested that those who quit smoking will do so
early in pregnancy (227). The second concern, underreporting, cannot be excluded as
a source of misclassification. As a consequence, the negative association between
maternal smoking and preeclampsia (Paper I) is probably not a spurious finding, and
may well be stronger than that reported by us. Furthermore, misclassification of
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smoking status would underestimate the effect of maternal smoking on birth size
(Paper II), and would also dilute possible differences between smokers and non-
smokers regarding umbilical cord blood levels of growth factors (Paper III  V).
However, a prevalence study regarding maternal smoking during pregnancy was
undertaken in Norway during the same period as we performed our study, and the
results from that study showed a prevalence of maternal smoking of 22 % (228). In
our study 26 % of the control women reported smoking during pregnancy, and we
therefore regard underreporting of smoking to be a modest problem in this study.
Gestational age as a potential confounding factor.
All studies in this field meet the problem that differences between groups may be
explained by differences in gestational age rather than by the factors that are used as
explanatory variables. We used several strategies to avoid confounding by gestational
age in our analyses.
Birth weight standards.  Most gestational-age adjusted birth weight
standards in international use are based on postnatally obtained weights.
However, for premature infants these standards have been criticised since the
underlying cause of premature delivery also may lead to restricted growth of the
fetus (102, 111). Therefore attempts have been made to derive birth weight
standards from ultrasound measurements of presumptive healthy fetuses, and as
expected, for premature infants these standards are slightly higher that those
obtained by postnatal measurement (112, 113). Since premature birth is
associated both with preeclampsia and with fetal growth restriction, in analyses
of the effect of preeclampsia on fetal growth it is important to use birth weight
standards that are properly adjusted for gestational age. Therefore, we chose
ultrasound based birth weight standards (Paper II, III and V) (113).
These standards were derived from a relatively small population (n = 86
women), but the observation that control infant birth weights were practically
identical to those expected from the ultrasound-based weight curves was
reassuring for the validity of the standards. However, all control infants were
born before 231 days of gestation, and among the 37 cases of preeclampsia with
infants born before 231 days of gestation (early onset preeclampsia) we cannot
exclude that applying ultrasound derived birth weight standards may have
slightly overestimated fetal growth restriction. A possible bias in the estimate is,
39
however, unlikely to explain the severe growth restriction in this subgroup of
preeclampsia (Paper II).
On the other hand, there is a positive correlation between maternal
weight and offsprings birth weight, and in our study high pre-pregnancy weight
was a risk factor for mild and late preeclampsia. Therefore, in these subgroups
of preeclampsia increased frequency of birth weights in the upper range of the
normal distribution should be expected. By applying population based birth
weight standards, we cannot exclude that our study has underestimated fetal
growth restriction in mild and late preeclampsia, and in these cases
individualised birth weight standards could have been an advantage.
Growth factors. Fetal growth is characterised by different stages; the organs
and the skeleton have their most important growth period before third trimester, and
the rapid increase in fetal size during third trimester is mainly determined by growth
of subcutaneous fat. The expression of a number of growth-associated factors
produced by the feto-maternal unit may therefore differ throughout gestation.
Accordingly, among controls we found a slightly negative association between
IGFBP-1 and gestational age after adjustment for birth weight (Paper V), whereas
cord blood leptin was strongly and positively related to gestational age (Paper IV).
Therefore, in the analyses of these two factors, comparisons between groups were
adjusted for differences in gestational age. For the leptin analyses, an additional
attempt was made to avoid confounding by gestational age; because cord blood leptin
was so strongly related to gestational age, and only a few controls were born before
34 weeks gestation, we restricted the leptin analyses to study subjects born at 34
weeks gestation or later in order to make proper comparisons between groups.
In contrast, the analyses of interleukin-6 showed that control levels of
umbilical cord plasma IL-6 were relatively constant throughout gestation (Paper III).
This observation is supported by a study of IL-6 in cord blood obtained by
chordoscentesis that showed no differences in cord levels of IL-6 within the range of
17  42 weeks gestation (229). Therefore, we could compare IL-6 levels among
subjects with early onset preeclampsia (gestational age 34 weeks or less) with control
levels despite the fact that most controls were born after 34 weeks gestation. The
same approach was used in the analyses of IGF-I and IGFBP-3 since no association
with gestational age was observed for these two markers.
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Incidence of preeclampsia.
The overall incidence of preeclampsia was 2.5% (Paper I), which is a relatively low
estimate compared to previous reports (6, 7, 10). In contrast to most previous studies
we included both nulliparous and parous women, and since nulliparity is an
established risk factor for preeclampsia (8, 39), we expected a relatively low
frequency. In addition, we applied a relatively narrow definition of preeclampsia,
which increases the specificity of the diagnosis on the costs of sensitivity. The narrow
inclusion criteria for preeclampsia in this study also influenced the distribution of
clinical subgroups; a high proportion of the preeclampsia group was classified as early
onset disease (11 %), and nearly one third was classified as severe preeclampsia.
2 Can the heterogeneous manifestations of preeclampsia be perpetuated by
different aetiological conditions?
Maternal risk factors.
Nulliparity and pre-pregnancy hypertension showed no specificity for any clinical
subgroup of preeclampsia, whereas the association with recurrent preeclampsia, pre-
pregnancy obesity, and maternal smoking varied substantially between the subgroups
(Paper I). Accordingly, pre-pregnancy obesity was strongly associated with mild and late
preeclampsia, whereas no association with severe preeclampsia was observed. This result
is in contrast to a previous study that observed a positive association between obesity and
severe preeclampsia (40). Most obese women in that study were, however, substantially
heavier than those classified as obese in our study, and this difference complicates direct
comparison between the studies.
Recurrent preeclampsia increased the risk for all subgroups of preeclampsia more
than ten - fold, but the association with early onset preeclampsia was particularly strong
(Adj. OR 42.4). Maternal smoking, in contrast, slightly reduced the risk of all subgroups
of preeclampsia, except for the early onset group where smoking had no risk reducing
effect. Early onset preeclampsia may be associated with high frequency of pre-existing
maternal disorders (17, 230), and the combination with a strong relation to recurrent
preeclampsia may indicate that potent pathogenetic mechanisms are activated in this
subgroup. Since the overall risk reducing effect of smoking was not very strong, one
interpretation of our results could be that a weak vasodilatating or hypovolemic effect of
41
smoking can not counteract the forceful mechanisms that increase blood pressure in early
onset preeclampsia.
There is strong evidence of a genetic predisposition to preeclampsia (53-55, 57-
60). However, the variation in patterns of maternal risk factors between clinical
subgroups of preeclampsia may indicate that different lines of pathogenesis perpetuate
the various clinical manifestations. One may therefor expect that a genetic predisposition
to early onset preeclampsia most likely differ from a predisposition to mild and late
disease.
Fetal growth restriction.
Mild and late onset preeclampsia had no clear effect on fetal growth, whereas in
severe and early onset preeclampsia 21% and 50% of the infants, respectively, were
classified as SGA (Paper II). In the early onset group, one third was classified as
having mild symptoms, but these infants birth weight was similar to those with
severe symptoms. Furthermore, in the severe preeclampsia group, the majority of
SGA infants were born at early gestation, and our results may suggest that gestational
age at debut of preeclampsia is a stronger indicator of fetal growth restriction than
severity of maternal symptoms.
 Corresponding to one previous report (97), we observed that parous women
had more than two-fold higher risk of SGA associated with preeclampsia compared to
the risk among nulliparous women. In our study, the increased risk among parous
women was attributable to a particularly high risk of SGA among women with
recurrent preeclampsia.
Thus, in accordance with some (8, 19), but not all previous studies (92), our
study showed that the impact of preeclampsia on fetal growth differed strongly
between subgroups of preeclampsia. Ness et al. hypothesised that heterogeneous
conditions may cause preeclampsia, and a distinction was made between cases where
the disease is confined to the maternal compartment, and cases related to placental
pathology and thereby include the fetus by restricting its growth (30). According to
this hypothesis, our results indicate that placental abnormalities are most likely to be
present in cases with severe, recurrent or early onset preeclampsia. Since our control
population contained few proper controls for comparison with the recurrent
preeclampsia group, in the analyses of growth factors we have focused on severe and
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early onset preeclampsia as subgroups likely to be accompanied by severe placenta
pathology.
Cord plasma levels of growth factors and subgroups of preeclampsia.
IL-6. Among controls, we found a weak, non-significant association between cord
plasma IL-6 and birth weight, whereas in preeclampsia, cord plasma IL-6 levels were
strongly and positively associated with birth weight. Subgroup analysis showed that
this association could be explained by particularly low IL-6 levels in cases with early-
onset disease. In cases with severe preeclampsia, cord plasma IL-6 levels were low
only if they belonged to the early-onset group, whereas those included in the late
onset group had IL-6 levels no different from controls. These results correspond to
previous studies where umbilical venous IL-6 was low in preeclampsia prior to 32
weeks gestation (231), but equal to control levels in preeclampsia closer to term
(131). Since cord levels of IL-6 may reflect the trophoblast production of IL-6, our
results may indicate that impaired trophoblast function is most likely to be present if
preeclampsia has an early onset.
IGF-I. Between mild preeclampsia and controls, there were no differences in
cord blood levels of IGF-I, IGFBP-1 and IGFBP-3. In severe and early onset
preeclampsia, in contrast, umbilical cord plasma IGF-I was approximately 50%
lower, and IGFBP-1 was more than twice as high as in controls, whereas we
observed no difference in IGFBP-3 levels between the groups. However,
whereas both birth weight and severe preeclampsia, independent of each other,
were associated with IGF-I, birth weight, but not severe preeclampsia, was
associated with IGFBP-1, after adjustment for gestational age. Thus, the low
levels of cord plasma IFG-I in severe and early preeclampsia were not
counteracted by alterations in binding protein levels, and the infants in these
subgroups of preeclampsia may have less IGF-I available in the circulation.
One previous study suggested that cord levels of IGF-I were reduced in
preeclampsia, beyond the reduction that was attributable to low birth weight
(162). In our large study, we could distinguish between clinical subgroups of
preeclampsia, and found low levels of cord plasma IGF-I in relation to
preeclampsia only in severe or early onset disease. Since the placenta may be a
strong determinant of circulating fetal IGF-I levels (147, 158), our results
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indicate that the placental function may be impaired mainly in cases of severe
and early preeclampsia.
Taken together, in severe and early preeclampsia cord levels of IL-6 and IGF-I
were lower than explained by the infants birth weight. These observations indicate an
effect of preeclampsia per se on cord plasma level of IL-6 and IGF-I if the disease is
severe, or has an early onset. Fetal growth was restricted in these two subgroups of
preeclampsia, and if cord levels of IL-6 and IGF-I reflect trophoblast function, our
results are in accordance with the hypothesis that placental impairment may
perpetuate preeclampsia only in cases where fetal growth is restricted (30). Thus, a
major distinction may exist between the aetiology of early and severe preeclampsia,
and the causes of mild and late preeclampsia.
3 Cord plasma levels of growth factors related to adult diseases
Leptin. Umbilical cord plasma leptin was higher in preeclampsia than in control
pregnancies, after adjustment for gestational age and ponderal index. Our result is in
contrast to two previous reports, but these studies were small, and may also have
failed to identify differences between groups by not adjusting properly for
confounding factors (186, 190).
Fetal hyperleptinemia may result from the pathogenetic processes that lead to
preeclampsia, and may reflect the high levels of leptin that is observed in placentas
from preeclamptic pregnancies (185). However, also maternal levels of leptin are
increased in preeclampsia (44, 186, 188), and hyperleptinemia is associated with
several risk factors for preeclampsia, including obesity and insulin resistance (187,
189). Thereby, hyperleptinemia in offspring of women with preeclampsia may be
related to a genetic or early environmental pre-disposition.
In adults, hyperleptinemia is associated with increased risk of cardiovascular
diseases (232), and low birth weight constitutes another severe risk factor (193, 198,
233-235). Sine cord plasma leptin was strongly related to gestational age, and most
controls were born after 34 weeks gestation, in the leptin analyses we included only
cases born within the same range of gestational age as control infants. In this subgrop
of preeclampsia (late onset), fetal growth was not materially restricted, nevertheless,
the infants were born with a pattern of metabolism that among adults is associated
with increased risk of cardiovascular disease. Thus, if newborn leptin levels are
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determinant for leptin levels in adulthood, either by in utero imprinting of metabolic
patterns, or as an indicator of a genetic pre-disposition to hyperleptinemia, our results
suggest that preeclampsia may constitute a risk factor for cardiovascular disease in
offspring beyond the risk that is attributable to low birth weight.
Taken together, the cord blood analyses in our study suggest that in
preeclampsia, offspring is born with altered patterns of growth and metabolism. These
alterations appear to differ strongly between subgroups of preeclampsia, and if adult
diseases are related to growth alterations in utero, one would expect that the impact of
preeclampsia on later diseases may differ according to the clinical manifestations of
preeclampsia. Accordingly, mild and late preeclampsia may constitute an entity where
the close relation to maternal obesity may indicate that the disorder is caused by
mechanisms that also cause other diseases in these women, including cardiovascular
disease and Type II diabetes. Furthermore, in spite of close to normal fetal growth in
these subgroups of preeclampsia, the results from the leptin-study suggest that these
infants metabolism was influenced by the maternal disease in a way that may
enhance their risk of cardiovascular disease in adulthood. About two thirds of a
population of preeclamptic pregnancies will be characterised by mild and late disease,
and these subgroups may therefor have major influence on results related to
preeclampsia in utero as explanatory variable. Thus, the observation that blood
pressure was increased at age 17 among females exposed to preeclampsia may
support our speculation that offspring in mild and late preeclampsia will have
increased risk of cardiovascular disease and related risk factors as adults (236).
IGF-I. In severe and early preeclampsia the maternal syndrome also includes
the fetus by restricting its growth. It has been suggested that mechanisms that restrict
fetal growth also may participate in cancer inhibition, as indicated by the reduced risk
of breast cancer in subjects with low birth weight, and among women with
preeclampsia (204, 205) and their female offspring (206, 207, 208). High levels of
IGF-I/II are linked to breast cancer pathogenesis, in experimental as well as clinical
studies (211, 212, 215). We observed particularly low levels of cord blood IGF-I in
severe and early onset preeclampsia, and if fetal IGF-I levels are important for later
cancer development, low frequency of breast cancer should be expected in offspring
of pregnancies with severe or early preeclampsia.
The GH-IGF axis is important also for postnatal somatic growth and growth of
blood vessels (237). Permanent alterations in IGF-I production and sensitivity by fetal
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undernutrition may thereby link fetal growth restriction to catch- up growth and raised
blood pressure in adulthood, and high body weight and hypertension may explain the
increased risk of Type II diabetes and cardiovascular disease that is observed in adults
with low birth weight (195). According to this hypothesis, the very low IFG-I levels
in early and severe preeclampsia may indicate that infants in these subgroups have a
particularly high risk of developing cardiovascular disease as adults. The maternal
risk of cardiovascular disease related to early preeclampsia is not clear; a recent
observation links preterm preeclampsia to increased risk of maternal death from
coronary heart disease (197), whereas in our study, maternal obesity, which is an
established risk factor for cardiovascular disease, did not increase the risk of severe
and early preeclampsia. In these subgroups of preeclampsia, umbilical IGF-I levels
were lower than indicated by the infants birth weight, and thereby, the intrauterine
influence on their IGF system may differ from the influence on the IGF system in
other growth restricted infants. Thus, whether infants with growth restriction related
to severe and early preeclampsia experience a similarly increased risk of
cardiovascular disease and its risk factors as other growth restricted infants should be
addressed in future studies.
4 Maternal smoking and fetal growth restriction
In control infants, maternal smoking was related to a reduction in birth weight of 4%,
and birth weight following preeclampsia in non-smokers was 3% lower than expected.
Birth weight in smokers with preeclampsia was reduced by 10%, and the combined
effect of smoking and preeclampsia on birth weight did not differ between subgroups
of preeclampsia. Thus, in contrast to some previous studies that suggested a synergy
effect of smoking and preeclampsia on fetal growth (8, 96, 225), our results indicate
that the effect of maternal smoking on fetal growth is added to the effect of
preeclampsia.
Maternal smoking had no clear influence on cord plasma IL-6, IGF-I and
IGFBP-1 in the preeclampsia group or among controls, after adjustment for birth
weight. In contrast, in the subgroups of preeclampsia that were associated with fetal
growth restriction, cord plasma IL-6 and IGF-I were significantly reduced. Cord
plasma IL-6 and IGF-I may reflect trophoblast function, and thereby, our study
indicates that trophoblast impairment is less likely to perpetuate fetal growth
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restriction in smoking than in preeclampsia. Also, the relatively weak effect of
maternal smoking on fetal growth makes the presence of severe placenta pathology
less likely among smokers.
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CONCLUSIONS
Nulliparity and high pre-pregnancy blood pressure increased the risk for all
subgroups of preeclampsia, whereas high pre-pregnancy weight increased the risk of
mild and late preeclampsia. The risk of early onset preeclampsia was particularly high in
recurrent disease and smoking decreased the risk of all subgroups of preeclampsia, exept
the early onset group. Thus, a major distinction may exist between the aetiology
underlying early onset preeclampsia, and the cause(s) of mild and late preeclampsia.
Pregnancy outcome in terms of fetal growth differed substantially between
subgroups of preeclampsia, and mild and late preeclampsia had little or no impact on
fetal growth. Thus, fetal growth restriction was mainly confined to cases with
recurrent, severe, or early onset preeclampsia, which indicates that placental
impairment is present mainly in these subgroups. Furthermore, debut of preeclampsia
at early gestation was a better indicator of fetal growth restriction than severity of
maternal symptoms.
In severe and early onset preeclampsia, umbilical cord plasma IL-6 and IGF-I
were lower than explained by the infants birth weight, which indicates an effect of
preeclampsia per se on cord levels of IL-6 and IGF-I in cases with severe and early
disease. Thus, if umbilical levels of IL-6 and IGF-I reflect trophoblast function, our
results may support the hypothesis that placental impairment perpetuates
preeclampsia only in cases where fetal growth is restricted.
In late onset preeclampsia, cord plasma leptin was higher in the preeclampsia
group than in the control group, after adjustment for gestational age and ponderal
index. Taken together with the analyses of IL-6 and IGF-I, these results suggest that
offspring in preeclamptic pregnancies are born with alterations in patterns of growth
and metabolism, and that these alterations differ substantially between subgroups of
preeclampsia. If intrauterine growth patterns are important for adult disease, our
results suggest that mild and late preeclampsia may be linked to increased risk of
cardiovascular disease in offspring, whereas early and severe preeclampsia may
reduce offsprings risk of cancer in adult life.
Maternal smoking added its effect on birth weight to the effect of
preeclampsia, indicating no synergy between those two factors on fetal growth
restriction. Also the umbilical cord blood analyses of growth factors indicate that
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smoking may influence fetal growth by mechanisms that are independent of
mechanisms in preeclampsia that also restrict growth.
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ERRATA
In thesis:
Page 9, line 14 and page 36, line 11: Insulin like growth factor I and its binding
protein-1 in umbilical cord plasma in relation to severe preeclampsia and birth weight:
a prospective investigation in Norway is replaced by Relationship of insulin-like
growth factor-I and insulin-like growth factor binding proteins in umbilical cord
plasma to preeclampsia and infant birth weight.
Page 16, line 9 : Folgero is replaced by Folgerø.
Page 21: Reference 131 is moved from line 21 to line 17.
Page 30, line 17: We obtained written consent from 323 cases and 632 controls is
replaced by We obtained written consent from 323 cases and 650 controls.
Page 30, line 23: blood from 270 cases an 611 controls for the analyses (Paper III)
is replaced by blood from 271 cases and 611 controls for the analyses (Paper III).
Page 32, line 21: intra-assay is replaced by inter-assay.
Page 39, line 23: after 34 weeks gestation i replaced by  at 34 weeks gestation or
later.
Page 43, line 17: Reference 134 is replaced by reference 186.
Page 52, line 4:  systemisk Lupus erythematosus is replaced by Systemisk Lupus
Erytematosus.
In Paper II:
Page 952, Table 2: Correct categories of pre-pregnancy weight: < 60, 60-79 and ≥ 80.
In Paper V:
Page 3, line 19: intra-assay coefficients of variation. Correction:  inter-assay
coefficients of variation.
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Leptin, the product of the obesity gene,1 is a hormone
mainly expressed in adipocytes. Through a negative feed-
back mechanism between adipose tissue and hypothala-
mic centers, leptin may contribute to the regulation of
obesity by inducing satiety and may stimulate energy ex-
penditure at the expense of storage.2 The regulation of
leptin is not fully understood, but a covariation with in-
sulin is documented.
Circulating leptin levels reflect body fat contents, and
the association with insulin has linked leptin to the 
insulin-resistance syndrome, which includes obesity, glu-
cose intolerance, and dyslipoproteinemia.3 In addition to
its relation to obesity, leptin may stimulate maturation of
the reproductive axis. There is a gender difference in lep-
tin, with higher concentrations in females than in males.4
In pregnancy, it has been shown that leptin is highly ex-
pressed in the placenta.5 The protein has been detected
in umbilical cord blood from week 18 of gestation, fol-
lowed by increased levels from the middle of the third
trimester toward term.6 This increase coincides with the
development of fetal adipose tissue, and the results from
some previous studies indicate that cord blood leptin is
positively correlated with fetal adiposity at birth.6-8 Com-
pared with later in life, however, leptin levels are much
higher in umbilical cord blood than the weight of the
fetus would indicate,9 and it has been hypothesized that
the high leptin concentrations are required to mobilize
fat stores to meet the energy demands of the newborn.9,10
Preeclampsia increases fetal risk of being born small
for gestational age, particularly in cases of early and re-
current disease.11 The growth-retarded infants exhibit
wasting of subcutaneous fat, and one would therefore
expect lower leptin levels in umbilical blood from
preeclamptic than from normotensive pregnancies.
However, 1 previous small study found no difference in
cord leptin levels between cases of preeclampsia and
controls with delivery at term.12 Preeclampsia is associ-
ated with maternal obesity, and maternal levels of circu-
lating leptin appear to be increased in preeclamptic
compared with normotensive pregnancies.12,13 Because
leptin may induce metabolic and circulatory changes
that are characteristic of preeclampsia,14 it has been
suggested that leptin may play a role in the pathogene-
sis of preeclampsia.12,13
The main aims of the present study were to compare
umbilical cord plasma levels of leptin between pregnan-
cies with preeclampsia and normotensive control preg-
nancies and to assess the relation between fetal adiposity
at birth and leptin levels. The study was based on a popu-
lation of approximately 13,000 consecutive births; we in-
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Umbilical cord plasma leptin is increased in preeclampsia
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OBJECTIVE: The objective of this study was to compare umbilical cord plasma leptin between infants of
mothers who experienced preeclampsia and infants of control subjects and to study the relation between
cord plasma leptin and infant obesity, as indicated by ponderal index.
STUDY DESIGN: On the basis of a population of approximately 13,000 deliveries, we compared cord
plasma leptin from preeclamptic (n = 256 women) and control pregnancies (n = 607 women) after taking the
differences in gestational age and ponderal index into account.
RESULTS: Cord plasma leptin increased strongly with gestational age, both in the preeclampsia group and
the control subjects (P < .01), but at each gestational age the preeclampsia group had higher leptin levels
than control subjects (P < .01). Adjustment for the higher ponderal index among control subjects (P < .05) did
not alter the difference in leptin levels between the groups.
CONCLUSION: We found higher levels of umbilical cord plasma leptin in infants of mothers who had 
preeclampsia (compared with infants of control subjects) after adjusting for differences in gestational age,
gender, and infant ponderal index. (Am J Obstet Gynecol 2002;186:427-32.)
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cluded 256 cases of preeclampsia and 607 control sub-
jects in the analyses.
Material and methods
Umbilical cord blood samples were collected in a
prospective study of pregnancy outcome that took place
from January 1993 to December 1995 at Rogaland Cen-
tral Hospital in Stavanger, Norway. The birthing clinic at
this hospital serves exclusively a region of approximately
239,000 inhabitants; there were 12,804 deliveries during
the study period.
The Norwegian Medical Birth Registry records infor-
mation on all deliveries that take place in Norway; we
searched the records to identify potential cases of pre-
eclampsia and to select population control subjects, as
previously described.11 Information from the Birth Reg-
istry was verified and supplemented with details from
hospital records, and we identified 307 singleton preg-
nant women who fulfilled the diagnostic criteria for pre-
eclampsia. After cases with culture-proven neonatal
sepsis (n = 1 case) and maternal diabetes mellitus (n = 4
cases) were excluded, umbilical cord blood was available
from 256 cases with preeclampsia. We used a definition
of preeclampsia that has been reported previously15 (ie,
persistent diastolic blood pressure of at least 90 mm Hg
had to develop after 20 weeks of gestation, and diastolic
blood pressure had to increase by at least 25 mm Hg). In
addition, proteinuria had to be present, and cut-off was
defined as 0.3 mg/L (semiquantitative dipstick, 1+) in at
least 1 urine sample after 20 weeks of gestation without
simultaneous urinary infection. Preeclampsia was classi-
fied as severe if the diastolic blood pressure increased to
at least 110 mm Hg, along with proteinuria 3+ on dip-
stick, or at least 500 mg/24 hours (n = 66 cases). All
other cases of preeclampsia were classified as mild (n =
190 cases). For comparison, the Medical Birth Registry
selected 2 groups of women without preeclampsia who
gave birth at the hospital during the same period, as pre-
viously described.11 In 1 group, control women gave
birth subsequent to women with preeclampsia, whereas
the other control group was randomly selected, but
matched to preeclampsia cases on maternal age. How-
ever, the use of each control group yielded nearly identi-
cal results, and we therefore pooled the groups to gain
statistical power. Among 619 women without preeclamp-
sia who were selected initially, we obtained cord blood
from 607 women, after excluding subjects with culture-
proven neonatal sepsis (n = 1 subject) and maternal dia-
betes mellitus (n = 1 subject).
Information on maternal smoking was obtained at ul-
trasound screening at 18 weeks of gestation, whereas all
other baseline data were obtained at the first maternal
visit around 12 weeks of pregnancy. Infant data were col-
lected from hospital records after the infant was dis-
charged from the hospital. Blood samples were collected
passively from the placental side of the umbilical cord
after delivery, in syringes that contained heparin. The
samples were chilled to 4°C for as long as 60 hours before
being centrifuged at 3000 rpm for 15 minutes; the plasma
was stored at –80°C until it was analyzed.
Gestational age at birth was calculated from routine ul-
trasonographic measurements of biparietal diameter at
18 weeks of gestation, according to Norwegian standard
curves. Ponderal index was calculated as a measure of
neonatal adiposity, as birth weight divided by the cubed
value of birth length by the equation 
(birth weight [g] · 100)
length (cm)3
In Table I, we have described some characteristics of the
study groups.
Assay. Leptin level in umbilical cord plasma was mea-
sured by a competitive radio immunoassay (Linco Re-
search, St. Charles, Minn) with the use of recombinant
125I-leptin as tracer. All samples were analyzed in dupli-
cate, and the detection limit of the assay was 0.4 ng/mL.
Leptin was detected in all but 4 samples. The intra-assay
coefficient of variation was always <10%, and the interas-
say variation was <11% for leptin values in the range be-
tween 19.5 and 2.2 ng/mL.
Table I. Maternal and fetal characteristics
Characteristic With preeclampsia (n = 256) Control subjects (n = 607)
Maternal age (y)* 26.9 ± 4.6† 28.2 ± 4.9
Nulliparous (%) 64† 36
Smoking (%) 18† 27
Cesarean section (%) 28† 5
Steroids (%) 12† 1
Gestational age (days)* 266 ± 22† 280 ± 11
Female gender (%) 51 50
Ponderal index (birth weight [g] · 100/length [cm]3)* 2.73 ± 0.32† 2.87 ± 0.27
Birth weight (g)* 3085 ± 848† 3599 ± 491
Cord plasma leptin levels (ng/mL)‡ 8.0 (10.0) 7.5 (8.9)
*Values are given as mean ± SD.
†P < .05, compared with control subjects.
‡Values are given as median (interquartile range).
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Statistical analyses. Leptin had a skewed distribution
and was therefore expressed as the median value in the
Tables, and transformed to natural logarithm when in-
cluded in the statistical analyses. The Student t test was
used to compare continuous variables between groups;
differences between proportions were assessed by chi-
square tests. We calculated quartile levels of ponderal
index on the basis of the distribution in the control pop-
ulation. Within the groups, we tested the linear associa-
tion (presented as P for trend) of leptin across quartiles
of ponderal index and adjusted for gestational age and
gender by multiple linear regression analysis. We calcu-
lated the ratio between transformed to natural logarithm
leptin and ponderal index and compared this ratio be-
tween the groups after adjusting for gestational age and
gender by multiple linear regression analyses. All statisti-
cal analyses were calculated with the Statistical Package
for the Social Science (SPSS), version 10.05 (SPSS, Inc,
Chicago, Ill).
Results
Umbilical cord plasma leptin levels increased strongly
with increasing gestational age (Fig 1), both in women
with preeclampsia and among control subjects (P < .01
for both groups). Among control subjects, only 6 infants
were born before 34 weeks of gestation, therefore subse-
quent analyses were restricted to pregnancies with dura-
tion *34 weeks.
Before the differences in gestational age were taken
into account, there was no clear difference in cord
plasma leptin between the preeclampsia group and con-
trol subjects (8.0 ng/mL [interquartile range, 10.0
ng/mL] vs 7.5 ng/mL [interquartile range, 8.9 ng/mL];
Table I). Infants in the preeclampsia group were, how-
ever, born at earlier gestation than the infants in the con-
trol group (266 vs 280 days; Table I). After adjustment for
gestational age, umbilical cord leptin levels were higher
in the preeclampsia group (P < .01), but additional ad-
justment for maternal smoking, mode of delivery, gender,
and prenatal administration of steroids did not influence
the results (data not shown). Furthermore, cases with
mild and severe preeclampsia showed no clear difference
in cord blood leptin levels when we adjusted for differ-
ences in ponderal index, gestational age, and gender be-
tween groups (data not shown).
Female newborns had higher cord plasma leptin levels
than male newborns, both within the preeclampsia group
(9.8 vs 6.6 ng/mL; P < .01) and among the control group
(9.5 vs 5.2 ng/mL; P < .01). In Table II, we compare cord
plasma leptin levels between the preeclampsia group and
the control group for each gender separately; the results
show that leptin levels were higher in preeclampsia for
both genders (P < .01).
The ponderal index was lower in the preeclampsia
group than in the control group (2.73 vs 2.87; P < .05;
Table I). However, in both groups, there was a consistent
increase in leptin levels with an increasing ponderal
index. This trend was also present after gender and ges-
tational age were taken into account (both P trend < .01;
Table III). To study the relation between leptin and pon-
Table III. Cord plasma leptin levels according to fetal ponderal index 
Preeclampsia Control subjects
Quartiles of ponderal index* n Leptin level (ng/mL)† P trend‡ n Leptin level (ng/mL)† P trend‡
Overall 223§ 8.0 (10.0) 601 7.5 (8.9)
<2.69 73 5.2 (8.7) 146 5.0 (6.2)
2.69-2.85 58 8.6 (9.6) 152 7.2 (7.3)
2.86-3.04 56 9.6 (14.7) 153 7.8 (9.4)
>3.05 36 11.3 (11.9) <.01 150 10.7 (10.8) <.01
*Equation: (weight  100)/length3.
†Median (interquartile range).
‡Test for linear trend of leptin levels across ordinal categories of ponderal index, adjusted for gestational age and gender by multiple
linear regression analyses.
§Numbers do not add up to total because of missing values.
Table II. Cord plasma leptin by infant gender
With preeclampsia Control subjects 
Gender n Leptin level (ng/mL)† n Leptin level (ng/mL)† P value*
Female 115 9.8 (12.2) 299 9.5 (9.8) .007
Male 111 6.6 (8.0) 302 5.2 (6.9) .002
*Comparison between infants of mothers with preeclampsia and of control subjects among female and male infants separately, ad-
justed for gestational age by multiple linear regression analyses.
†Median (interquartile range).
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deral index further, we calculated the ratio between cord
plasma leptin and ponderal index and displayed this re-
lation graphically by gestational age (Fig 2). Fig 2 shows
that, at each level of gestational age, the ratio was higher
in the preeclampsia group than in the control group 
(P < .01), except at 34 weeks of gestation at which time no
clear difference between groups was observed. At this ges-
tational age, however, there was a higher proportion of
male fetuses in the preeclampsia group (63%) than in
the control group (46%); because cord plasma leptin lev-
els were generally higher in the female fetuses, this dis-
parity could explain the lack of difference in the ratios
between leptin and ponderal index at early gestation.
Comment
Our study shows that umbilical cord plasma leptin lev-
els at birth are higher in infants of women with pre-
eclampsia than among control subjects. For both groups,
we found a strong increase in cord plasma leptin levels
with increasing gestational age at birth, but the pre-
eclampsia group had slightly, but consistently, higher lev-
els of umbilical leptin than the control group at each
gestational age. These results are in contrast to 1 previous
study that reported no increase in cord blood leptin level
in cases with preeclampsia who were born at term, com-
pared with control subjects.12 The study was, however,
small, and the comparison was not adjusted for potential
confounding by differences in ponderal index and sex
between groups.
In addition to gestational age, we also adjusted for
other factors that could potentially disturb the relation
with leptin between the preeclampsia and control
groups. However, further adjustment for the lower fre-
quency of maternal smoking and vaginal delivery in the
preeclampsia group did not materially alter the results.
Furthermore, a positive association between the pre-
natal administration of steroids and cord blood leptin
level has been reported.8 Therefore, we included this
factor in the multivariate analyses, but the higher level
of cord plasma leptin in preeclampsia was not ex-
plained by the more frequent administration of prena-
tal steroids in this group.
Some previous studies have found substantially higher
cord plasma leptin levels among female newborns com-
pared with male newborns,9,16 whereas other studies have
failed to show any difference by gender.17 Compared with
previous studies, our study included a larger number of
participants, and our results suggest that the gender di-
morphism in circulating leptin is likely to be present al-
ready at birth. It has been shown that testosterone may
suppress leptin synthesis and release from adipocytes,18
but at birth, circulating androgens do not vary much by
gender.19 This suggests that factors other than androgens
may be responsible for the higher umbilical leptin levels
among female offspring.
If fetal adipocytes contribute to cord blood leptin lev-
els, sex differences in fat deposition may constitute 1 such
factor. One large study observed no sex differences in
ponderal index at birth but reported increased deposi-
tions of subcutaneous fat, as measured by subscapular
skinfold thickness in female offspring.20 Therefore, the
statistical adjustment for ponderal index in our study may
not be sufficient to account for differences in body fat de-
positions between male and female infants, and this is a
shortcoming of our study.
Fig 1. Cord plasma leptin by gestational age in infants of mothers
with preeclampsia and among infants of control subjects. *The
comparison between groups is adjusted for differences in gesta-
tional age by multiple linear regression analyses (P > .01).
Fig 2. The ratio between cord plasma leptin and ponderal index
by gestational age in infants of mothers with preeclampsia and
among infants of control subjects. *The comparison between
groups is adjusted for differences in gestational age and gender
by multiple linear regression analyses (P > .01).
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The consistent sex dimorphism in cord plasma leptin
may support the hypothesis that the fetus contributes to
the production of the leptin that is detected in umbilical
cord blood. It is, however, difficult to attribute the higher
cord leptin levels in preeclampsia to fetal production,
particularly because infants in the preeclampsia group
had lower ponderal indices than did the control infants.
On the other hand, the expression of leptin is increased
in placental explants from preeclamptic pregnancies; in
trophoblast cell lines, hypoxia may stimulate the expres-
sion of leptin.21 Preeclampsia may be accompanied by re-
duced placental perfusion and subsequent placental
hypoxia; thereby the higher cord plasma leptin levels that
were observed in preeclampsia may be of placental ori-
gin. Leptin may induce lipolysis and gluconeogenesis2; in
preeclampsia, cord plasma hyperleptinemia may provide
substrates to maintain threatened cellular functions at
the expense of fetal body fat contents.
Maternal circulating levels of leptin appear to be in-
creased in preeclampsia12,13,22 and may be correlated
positively to fetal leptin levels.12 Placental contribution of
leptin to both compartments could explain this correla-
tion, but so could also a disrupted placental barrier. If ma-
ternal leptin were transported to the fetal circulation, this
could produce a positive correlation between maternal
and fetal leptin.12
Hyperleptinemia is 1 component of the insulin resis-
tance syndrome, which also includes glucose intolerance,
dyslipoproteinemia, and obesity.3 Because maternal obe-
sity strongly increases the risk of the development of 
preeclampsia, it has been hypothesized that insulin resis-
tance could be a risk factor for preeclampsia.12,13 Implicit
in this hypothesis was the suggestion that high levels of
maternal leptin before pregnancy also may increase the
risk of the development of preeclampsia. The results of
some studies may support this hypothesis; 1 study showed
that maternal leptin levels were higher in pregnant
women who later had preeclampsia,22 and another small
study found higher puerperal levels of leptin after
preeclamptic pregnancies, although this was statistically
insignificant.13 Our study was not designed to answer this
question, but the high umbilical leptin levels that we ob-
served in preeclampsia could be interpreted as a conse-
quence of high maternal leptin levels being an indicator
of increased risk of the development of preeclampsia.
Preeclampsia is a strong risk factor for fetal growth re-
striction, and some observations indicate that infants with
intrauterine growth restriction have increased risk of car-
diovascular diseases that are related to obesity and insulin
resistance later in life.23 These findings have been inter-
preted as a consequence of restricted growth in utero that
could have imprinted unfavorable metabolic patterns.24,25
If intrauterine leptin is an important determinant for the
set point of leptin later in life, one could speculate that the
higher levels of umbilical leptin in preeclampsia might be
related to the development of insulin resistance and car-
diovascular disease in adulthood.
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